<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416025</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00041916</org_study_id>
    <nct_id>NCT01416025</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing</brief_title>
  <acronym>VoriTDM</acronym>
  <official_title>A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized trial to study therapeutic drug monitoring
      (TDM) of voriconazole among patients with an invasive mould infection (IMI). The primary
      objective of this study will be to assess the effect of prospective voriconazole TDM on the
      composite of adverse events (AE) and clinical response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of patients who receive voriconazole as treatment for an IMI
      (proven, probable, and possible by the EORTC/MSG definitions), other than zygomycosis.
      Patients will be randomized to receive either standard dosing or dosing based on TDM,
      stratified by whether initial voriconazole therapy is PO or IV. Assessment of outcomes will
      be made 42 days after start of voriconazole. An additional follow up for safety reporting
      will be performed 4weeks after completion of voriconazole

      The patients will be randomized to:

        -  Prospective TDM: voriconazole dose will be adjusted based on per protocol obtained TDM
           levels, and

        -  Standard dosing: standard doses of voriconazole will be used.

      In the prospective TDM arm, voriconazole TDM will be performed in real time at each site and
      results will be reported to treating physicians for dose adjustment. All efforts will be
      taken to obtain results within 24 hours of blood sample collection. In the standard dosing
      arm, blood samples will be collected, stored, and batched for voriconazole levels to be
      tested retrospectively. Voriconazole plasma levels will be measured by validated high
      performance liquid chromatography (HPLC) assays as detailed. Voriconazole trough levels will
      be performed on Day Baseline/Screening, 5, 14, 28, and 42.

      Voriconazole peak level will be measured on Day 5. Trough voriconazole levels will be
      obtained in case of an event, defined as suspected drug-associated toxicity and/or clinical
      failure.

      Assessment of AEs for all patients will be monitored during the study and response to
      treatment will be assessed. The composite of overall AE/clinical failure will be assessed on
      day 42.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Failure</measure>
    <time_frame>42 days</time_frame>
    <description>The primary endpoint of the study will be a binary outcome, called Failure, defined as one of the following: measured at 42 days from initiation of drug administration:
Progression of underlying infection (clinical failure)
Death
Development of a voriconazole-associated SAE: LFTs, Rash, Visual disturbance, Neurologic abnormality (e.g: hallucinations)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Prospective TDM Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dosing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard doses of voriconazole will be used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prospective TDM Arm</intervention_name>
    <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
    <arm_group_label>Prospective TDM Arm</arm_group_label>
    <other_name>VFEND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for voriconazole administration: proven, probable, or possible IMI,
             excluding zygomycosis (based on the revised EORTC/MSG consensus definitions) [De Pauw,
             Clin Infect Dis. 2008; 46:1813].

          -  Male or female â‰¥12 years of age.

          -  Evidence of a personally signed and dated informed consent document in accordance with
             local regulatory and legal requirements indicating that the subject (or a legally
             acceptable representative) has been informed of all pertinent aspects of the study.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Known history of allergy, hypersensitivity or serious reaction to azole antifungals.

          -  Patients with aspergilloma or allergic bronchopulmonary aspergillosis (ABPA).

          -  Patients with chronic invasive aspergillosis with duration of symptoms or radiological
             finding for more than 4 weeks prior to study entry.

          -  Patients who are receiving and cannot discontinue the following drugs at least 24
             hours prior to randomization: terfenadine, pimozide or quinidine (because of the
             possibility of QT prolongation), St John's wort preparation.

          -  Patients receiving any of the following medications: sirolimus, rifampin, rifabutin,
             carbamazepine, long acting barbiturates (e.g., phenobarbital, mephobarbital),
             ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine).

          -  Receipt of more than 5 days of voriconazole as treatment prior to enrollment.

          -  Receipt of 7 days or more of systemic antifungal treatment for the current episode of
             IMI.

          -  Severe liver dysfunction (defined as total bilirubin, AST, ALT, or alkaline
             phosphatase &gt;5x upper limit of normal). Local laboratory results may be used to
             qualify individuals for enrollment.

          -  Patients with any condition which, in the opinion of the investigator, could affect
             patient safety, preclude evaluation of response, or make it unlikely that the proposed
             course of therapy can be completed.

          -  Patients who have already participated in this trial within the last 30 days.

          -  Patients with a high likelihood of death due to factors unrelated to IA (e.g., due to
             relapsed malignancy, severe GVHD, other underlying diseases, etc.) within 30 days
             following planned enrollment (investigator's discretion).

          -  Patients that weigh &lt;45 and &gt;120 kg, respectively, upon enrollment. If patients'
             weight is beyond those limits upon serial assessments during the study period, the
             study monitor should be contacted and decisions to keep or withdraw subject from the
             study will be made.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kieren Marr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <results_first_submitted>April 15, 2016</results_first_submitted>
  <results_first_submitted_qc>April 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Kieren Marr</investigator_full_name>
    <investigator_title>Professor of Medicine and Oncology</investigator_title>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Hematopoietic stem cell transplant</keyword>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Invasive mould infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prospective TDM Arm</title>
          <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Prospective TDM Arm: Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
        </group>
        <group group_id="P2">
          <title>Standard Dosing</title>
          <description>Standard doses of voriconazole will be used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prospective TDM Arm</title>
          <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Prospective TDM Arm: Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
        </group>
        <group group_id="B2">
          <title>Standard Dosing</title>
          <description>Standard doses of voriconazole will be used</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" lower_limit="49" upper_limit="83"/>
                    <measurement group_id="B2" value="59.1" lower_limit="28" upper_limit="84"/>
                    <measurement group_id="B3" value="62.5" lower_limit="28" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Failure</title>
        <description>The primary endpoint of the study will be a binary outcome, called Failure, defined as one of the following: measured at 42 days from initiation of drug administration:
Progression of underlying infection (clinical failure)
Death
Development of a voriconazole-associated SAE: LFTs, Rash, Visual disturbance, Neurologic abnormality (e.g: hallucinations)</description>
        <time_frame>42 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective TDM Arm</title>
            <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Prospective TDM Arm: Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
          </group>
          <group group_id="O2">
            <title>Standard Dosing</title>
            <description>Standard doses of voriconazole will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Failure</title>
          <description>The primary endpoint of the study will be a binary outcome, called Failure, defined as one of the following: measured at 42 days from initiation of drug administration:
Progression of underlying infection (clinical failure)
Death
Development of a voriconazole-associated SAE: LFTs, Rash, Visual disturbance, Neurologic abnormality (e.g: hallucinations)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prospective TDM Arm</title>
          <description>Voriconazole dose will be adjusted based on per protocol obtained TDM levels
Prospective TDM Arm: Voriconazole dose will be adjusted based on per protocol obtained TDM levels</description>
        </group>
        <group group_id="E2">
          <title>Standard Dosing</title>
          <description>Standard doses of voriconazole will be used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stop voriconazole</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Darin Ostrander</name_or_title>
      <organization>JohnHopkinsU</organization>
      <phone>(443) 287-6217</phone>
      <email>dostrander@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

